Resistance to cytotoxic therapy is the major problem in variant hairy cell leukemia (vHCL). In the presented case, immunotherapy with rituximab and allogeneic blood SCT induced a long-term remission, which was shown in the quantitative monitoring of molecular residual disease. Finally, the patient died 43 months after transplantation, owing to colon perforation caused by a disseminated infiltration of the colon by hairy cells.
A 60-year-old man with newly diagnosed vHCL was treated in November 1997 with two cycles of cladribine resulting in a PR, and was kept on maintenance therapy with IFN-a. Owing to progressive disease, polychemotherapy according to the VACOP-B protocol was started in April 1998 and switched to two cycles of Dexa-BEAM in June 1998, which resulted only in a PR. Splenectomy was performed 6 months later owing to persistent thrombocytopenia. A further 6 months later, the progressive disease was also refractory to cisplatin, ifosfamide and etoposide. Surprisingly, in July 1999, the application of four doses of rituximab (375 mg/m 2 ) led to a dramatic reduction in the circulating lymphoma cells by 5 orders of magnitude, as shown by quantitative CDR3-clone-specific PCR. During the following 12 months, the number of circulating peripheral hairy cells increased at a very slow steady rate. Thereafter, single doses of rituximab had to be given at decreasing intervals from 3 months to 4 weeks because the molecular response became less effective during this phase, indicating the development of resistance to rituximab. This could be shown by a decreasing reduction of peripheral lymphoma cells from 5 log to 2.5 log by single doses of rituximab, as well as a faster reappearance after every single infusion ( Figure 1a ). After conditioning with treosulfan (30 g/m 2 ), fludarabine (150 mg/m 2 ) and anti-thymocyte-globulin (380 mg), the patient was allografted with 7.59 Â 10 6 non-manipulated CD34 þ cells/kg from a matched unrelated donor. 1 Immunosuppression and anti-infective prophylaxis followed standard protocols. After an uneventful course without acute GvHD and rapid haematological reconstitution, the patient achieved a clinical and molecular remission. Four months after blood SCT, circulating lymphoma cells were detected again by PCR and an increase of 3 log units was found within 3 months (from o1 to B1000/100 000 PBMNC; Figure 1b) . Cyclosporine was rapidly tapered and combined with one infusion of rituximab. Circulating lymphoma cells disappeared within 4 weeks and the patient was in complete clinical remission as well as molecular remission lasting for about 30 months. The patient developed mild cutaneous chronic GvHD requiring intermittently low doses of prednisone. Two consecutive blood samples taken 36 and 39 months after allogeneic transplantation showed a moderate increase in lymphoma cells. The calculated increase of circulating hairy cells was within 2 log, and so did not fulfil our criteria of a molecular relapse (42 log). At 43 months after transplantation, the patient developed a fatal colon perforation caused by a disseminated infiltration of hairy cells. Blood samples obtained a few weeks before death were analysed post mortem. The results (Figure 1b Rituximab seems to be an effective treatment for vHCL, 2 as supported by the data presented. A clinical remission of about 1 year was achieved by treatment with the mAb after the failure of conventional chemotherapy. In addition, the quantitative determination of leukaemiaand clone-specific CDR3 rearrangements by real-time PCR is a very helpful tool to detect the molecular relapse before clinical manifestation and to use individualized therapeutic approaches. By applying this method, we were able to show a progressive development of resistance during repeated administrations of rituximab. Therefore, the patient was treated with allogeneic peripheral blood SCT and a clinical as well as molecular remission lasting for 3.5 years was reached, presumably owing to a GvL effect. The data shown in Figure 1b suggest that the GvL effect induced by rapidly tapered immunosuppression may be enhanced by a rapid reduction of the total tumour cell burden owing to treatment with rituximab. A comparable finding has also been reported in a patient with a cerebral relapse of high-grade malignant lymphoma after an allogeneic transplant. 3 To our knowledge, this is the first case of a vHCL that showed an intra-abdominal tumorous (chloroma-like) relapse after allogeneic transplantation. It has to be pointed out that this relapse occurred in the presence of a limited chronic GvHD.
